Covagen, Mitsubishi in deal for bispecific FynomAbs

Covagen AG (Zurich, Switzerland) will use its Fynomer protein engineering technology to develop bispecific

Read the full 147 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE